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Background: Guidelines recommend antiplatelet agents (APs) for patients hospitalized with acute coronary syndromes (ACS). We examined 
compliance and usage of clopidogrel (C) in discharged ACS patients, and cardiovascular (CV) events and major bleeding readmissions rates and 
costs of care in United States (US) clinical practice.
Methods: ACS patients (IMS Lifelink Health Plans Claims database) hospitalized 1/08-9/09, with ≥1-year follow-up, were divided according to 
initial AP or anticoagulant (AC) received in follow-up. Those receiving C within 7 days were classed as C-compliant (≥80% of days covered) or non-
compliant. Patients not receiving C, another AP or AC made up the No AP/AC group. Rates and costs for readmissions for myocardial infarction (MI), 
ACS, ischemic heart disease (IHD; ICD-9 410-414) and major bleeding (defined by ICD-9 codes) were determined.
Results: ST-elevation MI (STEMI), non-ST-elevation MI and unstable angina occurred in 39%, 52% and 9% of patients (n=25,588; mean age 62.6 
years); 57.4% of patients initially received C, 55.7% were C-compliant; 36.1% of patients did not receive any AP or AC during follow-up. C-compliant 
patients had more STEMI (51.4% vs 45.9%; P<0.001) and percutaneous coronary intervention (PCI) during index hospitalization (82.9% vs 68.8%; 
P<0.001) than noncompliant patients. No AP/AC patients had the lowest rates of STEMI (31.3%) and PCI during index hospitalization (33.6%; 
both P<0.0001 vs either C group). C-compliant patients were readmitted less frequently in Year 1 for MI (2.6% vs 3.9%), ACS (3.0% vs 4.4%), IHD 
(12.8% vs 14.6%) and major bleeding (0.5% vs 1.0%; all P<0.01). During 1-year follow-up, patient/month costs for IHD readmissions were lower 
for C-compliant ($2,139) and No AP/AC ($2,305) vs noncompliant patients ($2,714; P<0.0001). Major bleeding readmission costs were $1,101-
$1,573 for the three groups.
Conclusions: CV-related readmissions for ACS were lowest in C-compliant. CV readmission rates and costs were high and those for major bleeding 
were relatively low for C-compliant and noncompliant groups. New therapies, in addition to C, that decrease readmissions for CV causes with 
manageable bleeding risk would benefit US patients.
